Because the VprBP inhibitor B32B3 potently suppresses the growth of colon cancer cells, more detailed evaluation of its efficacy and combination use with other cancer grow inhibitors, for example, DNMT inhibitors, will be of particular interest. Here, DCAF1 is linked to colonic neoplasm.